4,732 Shares in Baxter International Inc. (NYSE:BAX) Acquired by Canandaigua National Bank & Trust Co.

Canandaigua National Bank & Trust Co. acquired a new stake in shares of Baxter International Inc. (NYSE:BAX) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 4,732 shares of the medical instruments supplier’s stock, valued at approximately $202,000.

Several other hedge funds also recently bought and sold shares of the business. Headinvest LLC purchased a new stake in shares of Baxter International in the third quarter valued at approximately $25,000. Bruce G. Allen Investments LLC purchased a new stake in shares of Baxter International in the 4th quarter worth $36,000. Turtle Creek Wealth Advisors LLC bought a new position in shares of Baxter International during the 4th quarter worth $37,000. Hexagon Capital Partners LLC increased its stake in shares of Baxter International by 205.4% during the fourth quarter. Hexagon Capital Partners LLC now owns 953 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 641 shares during the period. Finally, CKW Financial Group bought a new stake in shares of Baxter International in the fourth quarter valued at about $43,000. Institutional investors own 90.19% of the company’s stock.

Baxter International Stock Down 0.1 %

Shares of BAX traded down $0.05 during midday trading on Tuesday, hitting $33.86. 1,704,917 shares of the company’s stock traded hands, compared to its average volume of 3,967,846. The company has a current ratio of 1.48, a quick ratio of 1.01 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $17.25 billion, a price-to-earnings ratio of 6.52, a price-to-earnings-growth ratio of 1.76 and a beta of 0.61. Baxter International Inc. has a 1 year low of $31.01 and a 1 year high of $50.21. The firm’s fifty day moving average is $36.55 and its 200-day moving average is $38.87.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.04. The company had revenue of $3.59 billion for the quarter, compared to analyst estimates of $3.55 billion. Baxter International had a return on equity of 18.47% and a net margin of 17.79%. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.59 EPS. As a group, sell-side analysts anticipate that Baxter International Inc. will post 2.91 earnings per share for the current year.

Baxter International Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, July 1st. Shareholders of record on Friday, May 31st will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 3.43%. The ex-dividend date is Friday, May 31st. Baxter International’s dividend payout ratio is presently 22.31%.

Analysts Set New Price Targets

Several brokerages have issued reports on BAX. Citigroup dropped their target price on shares of Baxter International from $44.00 to $38.00 and set a “neutral” rating on the stock in a report on Wednesday, May 22nd. The Goldman Sachs Group started coverage on shares of Baxter International in a research note on Thursday, May 30th. They set a “neutral” rating and a $36.00 price objective on the stock. TD Cowen downgraded shares of Baxter International from a “buy” rating to a “hold” rating and set a $40.00 price objective for the company. in a research note on Friday, May 10th. Finally, Bank of America upped their target price on Baxter International from $42.00 to $45.00 and gave the stock a “neutral” rating in a report on Tuesday, March 5th. Nine research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $44.42.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.